Tag Archives: TRGM

Research Identifies a Potential New Path to Developing a Treatment for Chronic Pain

Los Angeles, September 8, 2015 – Targeted Medical Pharma to present new chronic pain research that reveals significant nervous system abnormalities among patients suffering from Fibromyalgia, at the 2015 PainWeek national conference in Las Vegas, Nevada. The study looked at 329 Fibromyalgia patients and 58 control patients all of whom wore Holter monitors for a 24 hour period to measure nervous system activity. The results of this study showed that patients with Fibromyalgia experience a significant decrease in both nighttime parasympathetic nervous system (PNS) activity and daytime sympathetic Continue reading →

New Research Finds a Link Between Obesity and Nutritional Deficiencies

Los Angeles, CA, April 27, 2015 — Obesity has reached epidemic proportions affecting nearly 78 million adults in the United States and has been linked with an increased risk of diabetes, heart disease, and cancer. Recent studies have suggested that obese patients have specific amino acid deficiencies that can contribute to obesity. The latest research report entitled “Nutritional Deficiencies Associated with Obesity,” published online in the Journal of Obesity and Weight Loss Therapy, highlights the specific amino acid and nutrient deficiencies that are commonly associated Continue reading →

Targeted Medical Pharma Announces New Partnership for Exclusive Distribution in Japan

Los Angeles, February 19,  2015 – Targeted Medical Pharma (OTCQB: TRGM), today announced the completion of an exclusive product distribution agreement with J-Network Inc., a  California-based company that specializes in distributing cosmetic and healthcare goods exclusively to Japan. The Agreement grants J-Network an exclusive one-year renewable license for the marketing and sales of the Company’s proprietary product, designed to improve sleep and immune function, in Japan. Under the terms of the Agreement, Targeted Medical Pharma will develop new products specific for import into the Japanese Continue reading →

Targeted Medical Pharma Announces Changes in Management and Board of Directors

New Management Structure Positions Company for Growth and Profitability Los Angeles, CA, January 29, 2015 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced several major changes that streamline operations and signify a commitment to revenue growth, cost containment and profitability. The Company has appointed Kim Giffoni, a co-founder and former Vice President of Foreign Sales at Targeted Medical Pharma, as the Chief Executive Officer. Dr. David Silver, former Chief Operating Officer and President at the Company, has been appointed Chief Medical Officer, and Marcus Continue reading →

Targeted Medical Pharma’s New Approach to Pain Management Targets Epidemic of Opioid and NSAID Over-Prescribing

White Paper explores Theramine® as a Safe and Clinically Effective Alternative to Common Pain Medications  Los Angeles, CA, October 6, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), recently published the White Paper: Innovations in Pain Management discussing the epidemic of pain, the dangers of commonly prescribed pain medications and the benefits of Theramine, as a clinically effective alternative to opioids and nonsteroidal anti-inflammatory (NSAID) drugs for the management of back pain and inflammation. According to Consumer Reports, the overuse of opioid pain medications has reached epidemic Continue reading →

Clinical Trial Results Confirm Amino Acid Based Medical Food Theramine® More Effective at Improving Chronic Back Pain than NSAID Pain Medications

Los Angeles, CA, September  23, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development company, announced the results of a second, double-blind clinical trial which confirmed that Theramine was shown not only to be more effective than ibuprofen in reducing low back pain, but also demonstrated a significant reduction in measures of inflammation. In this 28 day, multi-center trial, subjects taking Theramine as either a standalone medication or in conjunction with a low dose ibuprofen, demonstrated a significant reduction in both Continue reading →

Targeted Medical Pharma to Present at Sachs Associated 14th Annual Biotech in Europe Forum for Global Partnering and Investment

Los Angeles, September 16, 2014 — Targeted Medical Pharma (OTCQB:TRGM), today announced that William Shell, M.D., Chairman, CSO and CEO  is scheduled to present the latest company information regarding the advances in therapeutic nutrition and medical foods technology, at the 14th Annual Biotech in Europe Forum at the Congress Center in Basel, Switzerland. The presentation is scheduled for September 30th, 2014 at 11:45 am in the Lima Room. Dr. Shell will also be a panelist in the discussion regarding advancements in Neuroscience at 3:30 pm. Additional information Continue reading →

Targeted Medical Pharma Reports Second Quarter 2014 Financial Results

Los Angeles, CA, August 14, 2014 – Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced financial results for its second quarter ended June 30, 2014.  The Company posted increased revenues, gross profit and an increase in net income before interest, taxes, depreciation and amortization, and stock based compensation (Adjusted EBITDA*) on a quarter-over-quarter basis. Financial Overview Quarter-over-Quarter Comparison: Financial results for the three months ended June 30, 2014 compared to the three months ended June 30, 2013 Total revenue of $2.2 million, a 16% improvement Continue reading →

Targeted Medical Pharma Appoints Two New Independent Members to the Board of Directors

 Health Care Veteran Kerry Weems and Corporate Finance Expert Paul Pelosi, Jr. Join the Advisory Team Los Angeles, CA, June 13, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the addition of two independent members to the Company’s board of directors. The Company welcomes back health care specialist Kerry Weems to the board as an independent director and chairman of the Nominating and Governance Committee, as well as corporate finance expert Paul Pelosi, Jr. as an independent director. A nationally respected expert in Continue reading →

Targeted Medical Pharma to Present at the Third Annual Marcum MicroCap Conference

Los Angeles, CA –  May 23, 2014 – Targeted Medical Pharma (OTCQB: TRGM), a leader in the medical food manufacturing sector, announced today that it will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel. The Company’s presentation by William Shell M.D., Chief Executive Officer and Chief Science Officer, is scheduled to begin at 11:30 a.m. ET. The annual Marcum MicroCap Conference is a signature showcase for superior quality, Continue reading →